 "Cipla finalises Algeria JV plan with Biopharm SPA")
Cipla has firmed up its plan to manufacture and market respiratory products in Algeria in a joint venture partnership.
On Wednesday, the drug maker announced that it has signed a definitive agreement with its local partner Biopharm SPA for establishing a joint venture company. The deal will enable Cipla to get a front end presence in Algerian market.
The two sides had signed a binding term sheet in February and committed an investment of $15 million. As per the agreement Cipla would hold 40% stake in the company and invest $6 million.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app